Our data have shown that IFX therapy could downregulate Th1/Th17-associated proinflammatory cytokines and promote IL-25 production, consistent with previous work showing that serum level of IL-23 was significantly decreased in rheumatoid arthritis patients treated with IFX [33]. Here, IL23A is linked to rheumatoid arthritis.